Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $97.00 price objective on the biotechnology company’s stock. Other analysts also recently issued reports about the company. Raymond James raised their […]
More Stories
Howden Joinery Group (OTCMKTS:HWDJY) Reaches New 12-Month Low – What’s Next?
Shares of Howden Joinery Group Plc (OTCMKTS:HWDJY – Get Free Report) reached a new 52-week low during mid-day trading on...
Insider Buying: 374Water Inc. (NASDAQ:SCWO) General Counsel Acquires 10,800 Shares of Stock
374Water Inc. (NASDAQ:SCWO – Get Free Report) General Counsel Peter Mandel acquired 10,800 shares of the business’s stock in a...
Ross Stores (NASDAQ:ROST) Downgraded by StockNews.com to Hold
Ross Stores (NASDAQ:ROST – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in...
Occidental Petroleum (NYSE:OXY) Stock Rating Upgraded by StockNews.com
Occidental Petroleum (NYSE:OXY – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to...
Kratos Defense & Security Solutions (NASDAQ:KTOS) Cut to Sell at StockNews.com
Kratos Defense & Security Solutions (NASDAQ:KTOS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold”...
Trump Attends Starship Launch With Musk
By T.J. Muscaro President-elect Donald Trump attended the latest launch of Elon Musk’s Starship on Nov. 19 in South Texas....